Skip to main content
Top
Published in: Clinical and Translational Oncology 2/2019

01-02-2019 | Review Article

Do locally advanced and metastatic human epithelial cancers evolve in ‘placental/decidual-like microenvironments’?

Author: M. Hernández-Bronchud

Published in: Clinical and Translational Oncology | Issue 2/2019

Login to get access

Abstract

Successful tumor microenvironments eventually kill the host. They are not only meant to nourish and protect tumor development, but to give them the right “soil” for perpetual malignant properties such as tissue invasion and metastasis. This can only be achieved if cancers avoid immune vigilance. A similar situation occurs in mammalian placental pregnancy but feto-maternal tolerance is required for a correct physiological process only until birth. Once a cancer microenvironment has acquired the genetic and epigenetic “placental immune editing switches” (PIES) phenotype, it seems likely that it will keep them “available”, whenever needed, for the rest of its development, because it gives cellular clones a competitive advantage to pass unnoticed by the host’s immune system. This allows primary cancers and their metastasis to continue growing in spite of new and changing antigenic landscapes.
Literature
1.
go back to reference Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004;6:17–32.CrossRefPubMed Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004;6:17–32.CrossRefPubMed
2.
go back to reference Bar J, Feniger-Barish R, Lukashchuk N, Shaham H, Moskovits N, Goldfinger N, et al. Cancer cells suppress p53 in adjacent fibroblasts. Oncogene. 2009;28:933–6.CrossRefPubMed Bar J, Feniger-Barish R, Lukashchuk N, Shaham H, Moskovits N, Goldfinger N, et al. Cancer cells suppress p53 in adjacent fibroblasts. Oncogene. 2009;28:933–6.CrossRefPubMed
4.
go back to reference Carmona-Fontaine C, Deforet M, Akkari L, Thompson CB, Joyce JA, Xavier JB. Metabolic origins of spatial organization in the tumor microenvironment. Proc Natl Acad Sci USA. 2017;114:2934–9.CrossRefPubMedPubMedCentral Carmona-Fontaine C, Deforet M, Akkari L, Thompson CB, Joyce JA, Xavier JB. Metabolic origins of spatial organization in the tumor microenvironment. Proc Natl Acad Sci USA. 2017;114:2934–9.CrossRefPubMedPubMedCentral
5.
6.
go back to reference Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med. 2012;18:1224–31.CrossRefPubMed Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med. 2012;18:1224–31.CrossRefPubMed
7.
go back to reference Bigley AB, Simpson RJ. NK cells and exercise: implications for cancer immunotherapy and survivorship. Discov Med. 2015;19:433–45.PubMed Bigley AB, Simpson RJ. NK cells and exercise: implications for cancer immunotherapy and survivorship. Discov Med. 2015;19:433–45.PubMed
8.
go back to reference Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC, et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology. 1994;107:369–78.CrossRefPubMed Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC, et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology. 1994;107:369–78.CrossRefPubMed
9.
go back to reference Bronte V, Brandau S, Chen S-H, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.CrossRefPubMedPubMedCentral Bronte V, Brandau S, Chen S-H, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.CrossRefPubMedPubMedCentral
10.
go back to reference Casazza A, Laoui D, Wenes M, Rizzolio S, Bassani N, Mambretti M, et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell. 2013;24:695–709.CrossRefPubMed Casazza A, Laoui D, Wenes M, Rizzolio S, Bassani N, Mambretti M, et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell. 2013;24:695–709.CrossRefPubMed
11.
go back to reference Catanzaro JM, Sheshadri N, Pan J-A, Sun Y, Shi C, Li J, et al. Oncogenic Ras induces inflammatory cytokine production by upregulating the squamous cell carcinoma antigens SerpinB3/B4. Nat Commun. 2014;5:3729.CrossRefPubMed Catanzaro JM, Sheshadri N, Pan J-A, Sun Y, Shi C, Li J, et al. Oncogenic Ras induces inflammatory cytokine production by upregulating the squamous cell carcinoma antigens SerpinB3/B4. Nat Commun. 2014;5:3729.CrossRefPubMed
12.
go back to reference Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28:1368–79.CrossRefPubMed Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28:1368–79.CrossRefPubMed
14.
go back to reference Chiba T, Marusawa H, Seno H, Watanabe N. Mechanism for gastric cancer development by Helicobacter pylori infection. J Gastroenterol Hepatol. 2008;23:1175–81.CrossRefPubMed Chiba T, Marusawa H, Seno H, Watanabe N. Mechanism for gastric cancer development by Helicobacter pylori infection. J Gastroenterol Hepatol. 2008;23:1175–81.CrossRefPubMed
17.
go back to reference Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, et al. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell. 2013;23:634–46.CrossRefPubMedPubMedCentral Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, et al. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell. 2013;23:634–46.CrossRefPubMedPubMedCentral
18.
go back to reference Coppé J-P, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6:2853–68.CrossRefPubMed Coppé J-P, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6:2853–68.CrossRefPubMed
20.
go back to reference De Boeck A, Hendrix A, Maynard D, Van Bockstal M, Daniëls A, Pauwels P, et al. Differential secretome analysis of cancer-associated fibroblasts and bone marrow-derived precursors to identify microenvironmental regulators of colon cancer progression. Proteomics. 2013;13:379–88.CrossRefPubMed De Boeck A, Hendrix A, Maynard D, Van Bockstal M, Daniëls A, Pauwels P, et al. Differential secretome analysis of cancer-associated fibroblasts and bone marrow-derived precursors to identify microenvironmental regulators of colon cancer progression. Proteomics. 2013;13:379–88.CrossRefPubMed
21.
go back to reference Di Minin G, Bellazzo A, Dal Ferro M, Chiaruttini G, Nuzzo S, Bicciato S, et al. Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP. Mol Cell. 2014;56:617–29.CrossRefPubMed Di Minin G, Bellazzo A, Dal Ferro M, Chiaruttini G, Nuzzo S, Bicciato S, et al. Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP. Mol Cell. 2014;56:617–29.CrossRefPubMed
22.
go back to reference Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13:759–71.CrossRefPubMed Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13:759–71.CrossRefPubMed
23.
go back to reference Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15:385–403.CrossRefPubMed Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15:385–403.CrossRefPubMed
24.
go back to reference De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017;17:457–74.CrossRefPubMed De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017;17:457–74.CrossRefPubMed
25.
go back to reference Holtan SG, Creedon DJ, Haluska P, Markovic SN. Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc. 2009;84:985–1000.CrossRefPubMedPubMedCentral Holtan SG, Creedon DJ, Haluska P, Markovic SN. Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc. 2009;84:985–1000.CrossRefPubMedPubMedCentral
26.
go back to reference Franklin RA, Liao W, Sarkar A, Kim MV, Bivona MR, Liu K, et al. The cellular and molecular origin of tumor-associated macrophages. Science. 2014;344:921–5.CrossRefPubMedPubMedCentral Franklin RA, Liao W, Sarkar A, Kim MV, Bivona MR, Liu K, et al. The cellular and molecular origin of tumor-associated macrophages. Science. 2014;344:921–5.CrossRefPubMedPubMedCentral
27.
go back to reference Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97–103.CrossRefPubMed Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97–103.CrossRefPubMed
28.
29.
go back to reference Bronchud MH, Tresserra F, Xu W, Warren S, Cusido M, Zantop B, et al. Placental immune editing switch (PIES): learning about immunomodulatory pathways from a unique case report. Oncotarget. 2016;7:83817–27.CrossRefPubMedPubMedCentral Bronchud MH, Tresserra F, Xu W, Warren S, Cusido M, Zantop B, et al. Placental immune editing switch (PIES): learning about immunomodulatory pathways from a unique case report. Oncotarget. 2016;7:83817–27.CrossRefPubMedPubMedCentral
30.
go back to reference Bronchud MH, Tresserra F, Zantop BS. Epigenetic changes found in uterine decidual and placental tissues can also be found in the breast cancer microenvironment of the same unique patient: description and potential interpretations. Oncotarget. 2018;9:6028–41.CrossRefPubMed Bronchud MH, Tresserra F, Zantop BS. Epigenetic changes found in uterine decidual and placental tissues can also be found in the breast cancer microenvironment of the same unique patient: description and potential interpretations. Oncotarget. 2018;9:6028–41.CrossRefPubMed
32.
go back to reference Nagy A, Gócza E, Diaz EM, Prideaux VR, Iványi E, Markkula M, et al. Embryonic stem cells alone are able to support fetal development in the mouse. Development. 1990;110:815–21.PubMed Nagy A, Gócza E, Diaz EM, Prideaux VR, Iványi E, Markkula M, et al. Embryonic stem cells alone are able to support fetal development in the mouse. Development. 1990;110:815–21.PubMed
33.
go back to reference Tanaka S, Kunath T, Hadjantonakis AK, Nagy A, Rossant J. Promotion of trophoblast stem cell proliferation by FGF4. Science. 1998;282:2072–5.CrossRefPubMed Tanaka S, Kunath T, Hadjantonakis AK, Nagy A, Rossant J. Promotion of trophoblast stem cell proliferation by FGF4. Science. 1998;282:2072–5.CrossRefPubMed
34.
go back to reference Kunath T, Arnaud D, Uy GD, Okamoto I, Chureau C, Yamanaka Y, et al. Imprinted X-inactivation in extra-embryonic endoderm cell lines from mouse blastocysts. Development. 2005;132:1649–61.CrossRefPubMed Kunath T, Arnaud D, Uy GD, Okamoto I, Chureau C, Yamanaka Y, et al. Imprinted X-inactivation in extra-embryonic endoderm cell lines from mouse blastocysts. Development. 2005;132:1649–61.CrossRefPubMed
35.
go back to reference Lu C-W, Yabuuchi A, Chen L, Viswanathan S, Kim K, Daley GQ. Ras-MAPK signaling promotes trophectoderm formation from embryonic stem cells and mouse embryos. Nat Genet. 2008;40:921–6.CrossRefPubMedPubMedCentral Lu C-W, Yabuuchi A, Chen L, Viswanathan S, Kim K, Daley GQ. Ras-MAPK signaling promotes trophectoderm formation from embryonic stem cells and mouse embryos. Nat Genet. 2008;40:921–6.CrossRefPubMedPubMedCentral
36.
go back to reference Erb TM, Schneider C, Mucko SE, Sanfilippo JS, Lowry NC, Desai MN, et al. Paracrine and epigenetic control of trophectoderm differentiation from human embryonic stem cells: the role of bone morphogenic protein 4 and histone deacetylases. Stem Cells Dev. 2011;20:1601–14.CrossRefPubMedPubMedCentral Erb TM, Schneider C, Mucko SE, Sanfilippo JS, Lowry NC, Desai MN, et al. Paracrine and epigenetic control of trophectoderm differentiation from human embryonic stem cells: the role of bone morphogenic protein 4 and histone deacetylases. Stem Cells Dev. 2011;20:1601–14.CrossRefPubMedPubMedCentral
37.
go back to reference Frank HG. Chapter 10: placental development. In: Polin RA, Abman SH, Rowitch DH, Benitz WE, Fox WW, editors. Fetal and neonatal physiology. 5th ed. Philadelphia: Elsevier; 2017. Frank HG. Chapter 10: placental development. In: Polin RA, Abman SH, Rowitch DH, Benitz WE, Fox WW, editors. Fetal and neonatal physiology. 5th ed. Philadelphia: Elsevier; 2017.
38.
go back to reference Ferris E, Abegglen LM, Schiffman JD, Gregg C. Accelerated evolution in distinctive species reveals candidate elements for clinically relevant traits, including mutation and cancer resistance. Cell Rep. 2018;22:2742–55.CrossRefPubMedPubMedCentral Ferris E, Abegglen LM, Schiffman JD, Gregg C. Accelerated evolution in distinctive species reveals candidate elements for clinically relevant traits, including mutation and cancer resistance. Cell Rep. 2018;22:2742–55.CrossRefPubMedPubMedCentral
39.
go back to reference Rothschild BM, Tanke DH, Helbling M, Martin LD. Epidemiologic study of tumors in dinosaurs. Naturwissenschaften. 2003;90:495–500.CrossRefPubMed Rothschild BM, Tanke DH, Helbling M, Martin LD. Epidemiologic study of tumors in dinosaurs. Naturwissenschaften. 2003;90:495–500.CrossRefPubMed
41.
go back to reference Briggs JA, Weinreb C, Wagner DE, Megason S, Peshkin L, Kirschner MW, et al. The dynamics of gene expression in vertebrate embryogenesis at single-cell resolution. Science. 2018;360:eaar5780.CrossRefPubMedPubMedCentral Briggs JA, Weinreb C, Wagner DE, Megason S, Peshkin L, Kirschner MW, et al. The dynamics of gene expression in vertebrate embryogenesis at single-cell resolution. Science. 2018;360:eaar5780.CrossRefPubMedPubMedCentral
Metadata
Title
Do locally advanced and metastatic human epithelial cancers evolve in ‘placental/decidual-like microenvironments’?
Author
M. Hernández-Bronchud
Publication date
01-02-2019
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 2/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-018-1982-5

Other articles of this Issue 2/2019

Clinical and Translational Oncology 2/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine